Harpreet S Bajaj
Overview
Explore the profile of Harpreet S Bajaj including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
753
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rossing P, Benamar M, Cheng A, Kumar B, Laugesen C, Bajaj H
Diabetes Obes Metab
. 2025 Feb;
27(4):2259-2270.
PMID: 39930546
Aim: This post hoc analysis of ONWARDS 1-5 assessed the efficacy and hypoglycaemia outcomes with once-weekly insulin icodec (icodec) versus once-daily basal insulin comparators (degludec, glargine U100 or glargine U300)...
2.
The User's Guide to the Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
Butalia S, Bajaj H, Jain R, Leung K, Mansell K, Reichert S, et al.
Can J Diabetes
. 2024 Nov;
48(7):425-430.
PMID: 39550177
No abstract available.
3.
Shah B, Bajaj H, Butalia S, Dasgupta K, Eurich D, Jain R, et al.
Can J Diabetes
. 2024 Nov;
48(7):415-424.
PMID: 39550176
No abstract available.
4.
Wysham C, Bajaj H, Del Prato S, Franco D, Kiyosue A, Dahl D, et al.
N Engl J Med
. 2024 Sep;
391(23):2201-2211.
PMID: 39254740
Background: Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Data on safety and efficacy have been limited to small, phase 1 or phase 2 trials....
5.
Bajaj H, Asbjornsdottir B, Bari T, Begtrup K, Vilsboll T, Rosenstock J
Diabetes Obes Metab
. 2024 Jul;
26(9):3810-3820.
PMID: 38951942
Aim: To perform a participant-level post hoc meta-analysis of Phase 3a trials in type 2 diabetes (T2D) to characterize the hypoglycaemia safety and glycaemic efficacy of once-weekly insulin icodec (icodec)....
6.
Rosenstock J, Bajaj H, Lingvay I, Heller S
BMJ Open Diabetes Res Care
. 2024 May;
12(3).
PMID: 38749508
The objective of this review was to comprehensively present and summarize trends in reported rates of hypoglycemia with one or two times per day basal insulin analogs in individuals with...
7.
Bajaj H, Asbjornsdottir B, Carstensen L, Laugesen C, Mathieu C, Philis-Tsimikas A, et al.
Diabetes Care
. 2024 Feb;
47(4):729-738.
PMID: 38380954
Objective: This post hoc analysis assessed continuous glucose monitoring (CGM)-based metrics and hypoglycemia duration with once-weekly insulin icodec versus once-daily basal insulin analogs in insulin-experienced individuals with long-standing type 2...
8.
Tobe S, Mavrakanas T, Bajaj H, Levin A, Tangri N, Slee A, et al.
Diabetes Care
. 2024 Jan;
47(3):501-507.
PMID: 38252809
Objective: The study was undertaken because it was unknown whether the duration of type 2 diabetes modifies the effects of sodium-glucose cotransporter 2 inhibitor canagliflozin on cardiovascular (CV) and kidney...
9.
Sharma A, Razaghizad A, Joury A, Levin A, Bajaj H, Mancini G, et al.
J Am Heart Assoc
. 2024 Jan;
13(3):e031586.
PMID: 38240199
Background: This study evaluated the effects of canagliflozin in patients with type 2 diabetes with and without prevalent cardiovascular disease (secondary and primary prevention). Methods And Results: This was a...
10.
Patel H, Khunti K, Rodbard H, Bajaj H, Bray R, Kindracki Z, et al.
Diabetes Obes Metab
. 2023 Oct;
26(2):473-481.
PMID: 37853960
Aims: To evaluate gastrointestinal adverse events (AEs) and the impact of nausea, vomiting or diarrhoea (N/V/D) and any gastrointestinal (GI) AEs overall on weight change with tirzepatide across the SURPASS-1...